Gyungyub Gong Selected Research

Drug Therapy (Chemotherapy)

1/2022	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
1/2021	Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer.
1/2018	BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
4/2017	A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.
10/2016	Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
8/2015	Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
8/2015	Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
6/2014	Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
6/2012	Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy.
10/2008	Brain metastases in breast cancer: prognostic factors and management.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gyungyub Gong Research Topics

Disease

89	Breast Neoplasms (Breast Cancer) 12/2022 - 01/2002
72	Neoplasms (Cancer) 12/2022 - 01/2002
22	Neoplasm Metastasis (Metastasis) 04/2022 - 10/2005
14	Triple Negative Breast Neoplasms 01/2022 - 07/2011
6	Pathologic Complete Response 01/2022 - 06/2012
6	Thyroid Neoplasms (Thyroid Cancer) 01/2013 - 06/2004
5	Residual Neoplasm 01/2022 - 05/2014
5	Papillary Thyroid Cancer 09/2014 - 07/2011
4	Tertiary Lymphoid Structures 01/2019 - 08/2015
3	Carcinogenesis 01/2021 - 07/2008
3	Noninfiltrating Intraductal Carcinoma (DCIS) 10/2020 - 01/2016
3	Lymphatic Metastasis 09/2019 - 04/2017
3	Carcinoma (Carcinomatosis) 01/2016 - 11/2005
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 01/2004
2	Extranodal Extension 04/2014 - 04/2011
2	Hepatitis 09/2011 - 12/2007
2	Brain Neoplasms (Brain Tumor) 07/2011 - 10/2008
2	Graves Disease (Basedow Disease) 02/2010 - 06/2004
2	Adenocarcinoma 07/2008 - 07/2006
2	Hyperplasia 01/2006 - 11/2005
1	Stomach Neoplasms (Stomach Cancer) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Disease Progression 04/2021
1	Drug-Related Side Effects and Adverse Reactions 04/2021

Drug/Important Bio-Agent (IBA)

23	Hormones (Hormone)IBA 04/2021 - 09/2006
17	Estrogen ReceptorsIBA 12/2022 - 10/2005
17	human ERBB2 proteinIBA 10/2022 - 06/2011
10	Proteins (Proteins, Gene)FDA Link 10/2022 - 01/2002
10	Trastuzumab (Herceptin)FDA Link 08/2021 - 06/2012
10	Biomarkers (Surrogate Marker)IBA 02/2021 - 04/2011
7	Phenobarbital (Luminal)FDA Link 01/2022 - 09/2006
7	Progesterone Receptors (Progesterone Receptor)IBA 11/2020 - 07/2011
6	InterferonsIBA 10/2022 - 04/2016
6	ParaffinIBA 01/2022 - 11/2005
5	Formaldehyde (Formol)FDA Link 01/2022 - 06/2011
5	ErbB Receptors (EGF Receptor)IBA 08/2021 - 09/2006
5	AnthracyclinesIBA 02/2015 - 12/2006
5	Thyroglobulin FDA Link 01/2013 - 12/2008
4	HLA Antigens (Human Leukocyte Antigens)IBA 10/2022 - 04/2016
4	Messenger RNA (mRNA)IBA 11/2020 - 03/2007
4	Eosine Yellowish-(YS) (Eosin)IBA 10/2020 - 05/2008
4	Lapatinib (GW572016)FDA Link 10/2020 - 10/2016
4	Hematoxylin (Haematoxylon)IBA 10/2020 - 05/2008
4	taxaneIBA 03/2018 - 12/2006
4	Biological ProductsIBA 12/2017 - 06/2004
4	AntibodiesIBA 01/2013 - 06/2004
3	Estrogens (Estrogen)FDA Link 10/2022 - 12/2017
3	Letrozole (Femara)FDA LinkGeneric 04/2021 - 10/2016
3	Tamoxifen FDA LinkGeneric 01/2021 - 09/2019
3	Epidermal Growth Factor (EGF)IBA 10/2020 - 07/2011
3	Pharmaceutical PreparationsIBA 01/2019 - 12/2003
3	RNA (Ribonucleic Acid)IBA 01/2019 - 06/2016
3	HMGB1 Protein (HMG1)IBA 01/2019 - 12/2015
3	SilverIBA 12/2014 - 06/2011
3	anti-thyroglobulinIBA 01/2013 - 09/2006
3	DNA (Deoxyribonucleic Acid)IBA 09/2011 - 11/2005
2	EnzymesIBA 01/2021 - 01/2020
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021 - 10/2020
2	Leuprolide (Lupron)FDA LinkGeneric 01/2021 - 10/2020
2	Immune Checkpoint InhibitorsIBA 11/2020 - 01/2020
2	Interferon-gamma (Interferon, gamma)IBA 11/2020 - 01/2017
2	B7-H1 AntigenIBA 11/2020 - 01/2017
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2020 - 06/2015
2	Estradiol (Delestrogen)FDA LinkGeneric 10/2020 - 01/2019
2	Sirtuin 1IBA 07/2019 - 01/2016
2	HMGN1 Protein (HMGN1)IBA 01/2019 - 12/2015
2	Protein Kinases (Protein Kinase)IBA 01/2017 - 06/2016
2	High Mobility Group ProteinsIBA 09/2016 - 12/2015
2	Phosphotransferases (Kinase)IBA 06/2016 - 08/2014
2	HLA-A Antigens (HLA-A)IBA 05/2016 - 08/2015
2	CaspasesIBA 04/2014 - 09/2011
2	X-Linked Inhibitor of Apoptosis ProteinIBA 04/2014 - 09/2011
2	IodineIBA 10/2011 - 06/2004
2	Lamivudine (Epivir)FDA Link 09/2011 - 12/2007
2	Cadherins (E-Cadherin)IBA 04/2011 - 03/2009
2	Contrast MediaIBA 05/2008 - 03/2003
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 01/2022
1	Androgen Receptors (Androgen Receptor)IBA 01/2022
1	Collagenases (Collagenase)FDA Link 01/2022
1	ProteomeIBA 12/2021
1	Amsacrine (AMSA)IBA 12/2021
1	Carboplatin (JM8)FDA LinkGeneric 08/2021
1	pertuzumabIBA 08/2021
1	Docetaxel (Taxotere)FDA Link 08/2021
1	AntagomirsIBA 01/2021
1	EicosanoidsIBA 01/2021

Therapy/Procedure

23	Neoadjuvant Therapy 10/2022 - 06/2012
21	Therapeutics 04/2022 - 08/2010
12	Drug Therapy (Chemotherapy) 01/2022 - 12/2006
8	Mastectomy (Mammectomy) 01/2022 - 09/2013
7	Adjuvant Chemotherapy 01/2018 - 12/2007
6	Immunotherapy 12/2021 - 01/2015
6	Thyroidectomy 09/2014 - 10/2008
5	Mammaplasty (Breast Reconstruction) 01/2022 - 12/2020
4	Radiotherapy 04/2022 - 07/2011
4	Segmental Mastectomy (Lumpectomy) 01/2021 - 01/2018
4	Lymph Node Excision (Lymph Node Dissection) 01/2021 - 04/2011
2	Salvage Therapy 09/2015 - 12/2006
2	Combination Drug Therapy (Combination Chemotherapy) 08/2015 - 12/2006
2	Neck Dissection (Radical Neck Dissection) 09/2014 - 04/2014